drugset / Trial / NCT02120222

Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery

NCT02120222

Phase 1 Completed 8 enrolled Kari Kendra Karyopharm Therapeutics Inc · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase I clinical trial studies the side effects of selinexor in treating patients with melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as selinexor, may stop the growth of tumor cells, by stopping them from dividing.

Timeline

Start
2014-08-22
Primary completion
2018-04-08
Completion
2018-04-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Selinexor Other / unclassified Oral

Indications